(Q42982414)

12 November 2017

title

Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C. (English)

1 reference

12 November 2017

8

1 reference

12 November 2017

A Rodrigues

1

1 reference

12 November 2017

T Morgado

2

1 reference

12 November 2017

J Areias

3

1 reference

12 November 2017

F Silvestre

4

1 reference

12 November 2017

L Pinho

5

1 reference

12 November 2017

H Alves

6

1 reference

12 November 2017

A Castro-Henriques

7

1 reference

12 November 2017

S Guimarães

9

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

Transplantation Proceedings

12 November 2017

published in

1 reference

12 November 2017

volume

29

1 reference

12 November 2017

issue

1-2

1 reference

12 November 2017

page(s)

777-780

1 reference

Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

The impact of hepatitis C virus infection on renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Chronic viral hepatitis--benefits of current therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Interferon and hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

Hepatitis C in organ transplantation: its significance and influence on transplantation policies

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900098-X

7 January 2021

10.1016/S0041-1345(96)00098-X

Identifiers

DOI

1 reference

12 November 2017

1 reference